<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115996</url>
  </required_header>
  <id_info>
    <org_study_id>R3918-HV-1659</org_study_id>
    <secondary_id>2016-004208-70</secondary_id>
    <nct_id>NCT03115996</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously and Subcutaneously Administered Human Monoclonal Antibody REGN3918 in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous&#xD;
      (SC) doses and a multiple dose regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to single IV or SC or multiple dose treatment with REGN3918&#xD;
      or matched placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of TEAEs</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of REGN3918; single dose IV and SC</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Assessed via serum concentrations of REGN3918 over time; Area under the Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of REGN3918; single dose IV and repeated SC doses</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Assessed via serum concentrations of REGN3918 over time; peak concentration Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics profile of REGN3918</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Assessed by CH50 assay over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic exploratory analysis</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Peak concentration Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of REGN3918</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Assessed by measurement of anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>REGN3918 (Cohorts 1-4 &amp; 6a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Cohorts 1-4 &amp; 6a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts 1-4 and 6a will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN3918 (Cohort 5 &amp; 6b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5 and 6b will receive multiple doses of REGN3918</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Cohort 5 &amp; 6b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5 and 6b will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN3918</intervention_name>
    <description>Intravenous (IV) or Subcutaneous (SC)</description>
    <arm_group_label>REGN3918 (Cohort 5 &amp; 6b)</arm_group_label>
    <arm_group_label>REGN3918 (Cohorts 1-4 &amp; 6a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo (Cohort 5 &amp; 6b)</arm_group_label>
    <arm_group_label>Placebo (Cohorts 1-4 &amp; 6a)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        A subject must meet the follow criteria to be eligible for inclusion in the study:&#xD;
&#xD;
          1. Males and females from 18 to 50 years of age.&#xD;
&#xD;
          2. Subject is judged to be in good health based on medical history, physical examination,&#xD;
             vital sign measurements and laboratory safety tests performed at screening and/or&#xD;
             prior to administration of initial dose of study drug&#xD;
&#xD;
          3. The subject has a body mass index less than 30 kg/m2&#xD;
&#xD;
          4. Willingness to undergo vaccination and antibiotic prophylaxis against N. meningitides.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        A subject who meets any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Any clinically significant physical examination abnormalities observed during the&#xD;
             screening visit.&#xD;
&#xD;
          2. Hospitalization for any reason within 30 days of the screening visit&#xD;
&#xD;
          3. Persistent chronic or active recurring infection requiring treatment with antibiotics,&#xD;
             antivirals, or antifungals.&#xD;
&#xD;
          4. Subject has a history of meningococcal infection.&#xD;
&#xD;
          5. Carriers of Neisseria meningitides based on cultures from naso-pharyngeal swabs during&#xD;
             screening.&#xD;
&#xD;
          6. Subject has had a splenectomy.&#xD;
&#xD;
          7. Known allergy to penicillin class antibiotics&#xD;
&#xD;
          8. Known or suspected complement deficiency, or abnormal complement C3, C4 or CH50 during&#xD;
             screening.&#xD;
&#xD;
          9. Recent (within the previous 2 months) bacterial, protozoal, viral or parasite&#xD;
             infection requiring systemic treatment.&#xD;
&#xD;
         10. History of tuberculosis or systemic fungal diseases&#xD;
&#xD;
         11. HIV infection or HIV seropositivity at the screening visit&#xD;
&#xD;
         12. Positive HBsAg, HBcAb, or hepatitis C antibody at the screening visit&#xD;
&#xD;
         13. History of malignancy (except non-melanoma skin cancer or cervical in-situ)&#xD;
&#xD;
         14. Pregnant or breastfeeding women&#xD;
&#xD;
         15. Women of childbearing potential and men who are unwilling to practice highly effective&#xD;
             contraception prior to the initial dose/start of the first treatment, during the&#xD;
             study, and for at least 6 months after the last dose&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit (CRU) Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

